GLPwatch
Papers (12034)
Page 194 of 201, ranked by citation count.
- [Smeglutide inhibits high glucose-induced proliferation of myocardial fibroblasts by downregulating TGFβ/Smad3 signaling].
- Exenatide: excessive weight loss.
- Lixisenatide for type 2 diabetes.
- The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.
- Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks.
- Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
- Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.
- [Type 2 diabetes. Lixisenatide - effective in combination].
- Byetta update: what we've learned from experience.
- Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.
- Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's disease.
- The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report.
- Semaglutide in routine clinical practice: interesting news from real-world evidence.
- GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.
- Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis.
- Impact of semaglutide introduction on the use of triptans: an interrupted-time series.
- Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants.
- Synergistic role of exercise and liraglutide in modulating GLP-1R binding and metabolic outcomes: a combined computational and experimental study.
- Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
- Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?
- Laser Acupuncture versus Liraglutide in Treatment of Obesity: A Multi-Institutional Retrospective Cohort Study.
- Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
- Role of the GAPDH-mediated glycolysis-senescence axis in osteoarthritis chondrocytes and its modulation by semaglutide.
- Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.
- Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution.
- Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
- Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.
- Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.
- Any expectations from the more powerful dulaglutide?
- Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.
- TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends.
- [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].
- From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
- PHPI, MPBR, Part 2B (Product Code PHPI-L-01 or PHPI-E-01, Islets with Lisofylline or Exenatide).
- Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.
- Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.
- Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost.
- [Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity].
- Systemic Inflammatory Response Syndrome Following High-Dose Intravenous Glutathione-Containing Revitalising Solution in a Patient on Tirzepatide: A Case Report.
- GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.
- Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.
- Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.
- Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
- In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.
- Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium.
- [Case report: successful treatment with liraglutide in an insulin allergic patient with liver cirrhosis, hepatocellular carcinoma and poor glycemic control using high dose of insulin].
- Type 2 Diabetes in Pregnancy: Management and Novel Therapies.
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.
- Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.
- Type IIB PKA serves as the primary effector of Gs-coupled receptor-potentiated insulin secretion in mice by orchestrating ion channels and granule phenotype.
- Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.
- Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.
- Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.
- GLP-1 receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional optimization.
- Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.
- Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.
- Tirzepatide and Hydrochlorothiazide Coadministration in CKD: A Real-World Signal for Hypercalcemia Risk.
- Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.